973 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
PFE Pfizer, Inc. $43.01 $252.13B Downtrend
Article Searches
Glaxo Presents Encouraging Data on Endometrial Cancer Drug http://www.zacks.com/stock/news/362265/glaxo-presents-encouraging-data-on-endometrial-cancer-drug?cid=CS-ZC-FT-362265 Mar 20, 2019 - Glaxo (GSK) presents encouraging data from phase I/II study on endometrial cancer drug, dostarlimab.
Aerie (AERI) Starts Phase II Study on Eye Candidate AR-1105 http://www.zacks.com/stock/news/361538/aerie-aeri-starts-phase-ii-study-on-eye-candidate-ar-1105?cid=CS-ZC-FT-361538 Mar 19, 2019 - Aerie (AERI) begins dosing in a phase II study on AR-1105 for treating patients with macular edema due to retinal vein occlusion.
Allergan's Anti-Infective Gets FDA Nod for Pediatric Patients http://www.zacks.com/stock/news/361445/allergans-anti-infective-gets-fda-nod-for-pediatric-patients?cid=CS-ZC-FT-361445 Mar 19, 2019 - The FDA approves Allergan's (AGN) sNDA for the label expansion of its antibacterial medicine, Avycaz, to treat cUTI and cIAI in pediatric patients.
Bristol-Myers & Pfizer Release Phase IV Data on Eliquis http://www.zacks.com/stock/news/360914/bristol-myers-pfizer-release-phase-iv-data-on-eliquis?cid=CS-ZC-FT-360914 Mar 18, 2019 - Bristol-Myers (BMY) and partner Pfizer ) announce results from the phase IV - AUGUSTUS study evaluating Eliquis (apixaban) versus vitamin K antagonists (VKAs).
Pharma Stock Roundup: Regulatory Updates From MRK, PFE, J&J, AGN & Others http://www.zacks.com/stock/news/359854/pharma-stock-roundup-regulatory-updates-from-mrk-pfe-jj-agn-others?cid=CS-ZC-FT-359854 Mar 15, 2019 - Regulatory updates from J&J (JNJ), Merck (MRK), Roche (RHHBY), Pfizer (PFE) and others.
Lilly's Cyramza Successful in Phase III First-Line NSCLC Study http://www.zacks.com/stock/news/359294/lillys-cyramza-successful-in-phase-iii-first-line-nsclc-study?cid=CS-ZC-FT-359294 Mar 13, 2019 - Lilly's (LLY) cancer drug, Cyramza, in combination with erlotinib significantly delays disease progression in a phase III study on previously untreated patients with EGFR-mutated metastatic NSCLC.
Aerie (AERI) Receives FDA Nod for Rocklatan to Treat Glaucoma http://www.zacks.com/stock/news/359301/aerie-aeri-receives-fda-nod-for-rocklatan-to-treat-glaucoma?cid=CS-ZC-FT-359301 Mar 13, 2019 - Aerie (AERI) gets FDA approval for Rocklatan to reduce elevated IOP in patients with open-angle glaucoma or ocular hypertension and announces its 2019 revenue and cash burn outlook.
Lilly's Emgality Gets FDA Priority Review for Cluster Headache http://www.zacks.com/stock/news/357965/lillys-emgality-gets-fda-priority-review-for-cluster-headache?cid=CS-ZC-FT-357965 Mar 06, 2019 - Eli Lilly's (LLY) supplemental biologics license application for its migraine drug, Emgality, wins a priority review from the FDA for treating episodic cluster headache in adults.
AbbVie Gets CHMP Nod for Psoriasis Candidate Risankizumab http://www.zacks.com/stock/news/357598/abbvie-gets-chmp-nod-for-psoriasis-candidate-risankizumab?cid=CS-ZC-FT-357598 Mar 04, 2019 - AbbVie (ABBV) gets positive opinion of the CHMP recommending marketing approval for risankizumab for the treatment of moderate-to-severe plaque psoriasis.
Can This Biotech Puppy Run With the Big Dogs? https://www.fool.com/investing/2019/03/04/can-this-biotech-puppy-run-with-the-big-dogs.aspx?source=iedfolrf0000001 Mar 04, 2019 - Pfizer and Alnylam have a fierce, young contender with a chance to catch up in a big way.

Pages: 1234567891011...98

<<<Page 6>